For the Inventor, By the Inventor

Enter assignee name

Cambridge, MA, United States of America

Moderna Therapeutics, Inc.

Calculating rank

USPTO Granted Patents = 34

EPO Patents = 5

Trademarks = 7

Forward Citations = 3,728

Loading Chart...

Loading Chart...

21 inventors (with patents filed for the assignee):

Antonin De Fougerolles (29 out of 91 patents)

Tirtha Chakraborty (20 out of 45 patents)

Jason P Schrum (13 out of 30 patents)

4. Stephane Bancel (9 out of 31 patents)

5. Sayda Mahgoub Elbashir (8 out of 57 patents)

6. Kristy M Wood (8 out of 19 patents)

7. Ron Weiss (5 out of 38 patents)

8. Kenechi Ejebe (5 out of 20 patents)

9. Jeff Lynn Ellsworth (4 out of 25 patents)

10. Atanu Roy (4 out of 22 patents)

11. Susan Whoriskey (4 out of 15 patents)

12. Paul Hatala (4 out of 16 patents)

13. Noubar Boghos Afeyan (4 out of 77 patents)

14. Matthias John (3 out of 13 patents)

15. Justin Guild (3 out of 22 patents)

Core Competencies:

Modified Polynucleotides

Nucleic Acids

Protein Production

Engineered Nucleic Acids

Biologics

Microsphere Delivery

Cholesterol Levels

Lipid Nanoparticles

Apoptosis Inducing Factor

Granulysin

Erythropoietin

Blood Disorders

34 patents: Sort by Forward Citations

1. 9675668 - Modified polynucleotides encoding hepatitis A virus cellular receptor 2 (2017-06-13),

2. 9464124 - Engineered nucleic acids and methods of use thereof (2016-10-11),

3. 9447164 - Engineered nucleic acids and methods of use thereof (2016-09-20),

4. 9428535 - Modified nucleosides, nucleotides, and nucleic acids, and uses thereof (2016-08-30),

5. 9334328 - Modified nucleosides, nucleotides, and nucleic acids, and uses thereof (2016-05-10),

6. 9303079 - Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins (2016-04-05),

7. 9301993 - Modified polynucleotides encoding apoptosis inducing factor 1 (2016-04-05),

8. 9295689 - Formulation and delivery of PLGA microspheres (2016-03-29),

9. 9283287 - Modified polynucleotides for the production of nuclear proteins (2016-03-15),

10. 9271996 - Formulation and delivery of PLGA microspheres (2016-03-01),

11. 9255129 - Modified polynucleotides encoding SIAH E3 ubiquitin protein ligase 1 (2016-02-09),

12. 9254311 - Modified polynucleotides for the production of proteins (2016-02-09),

13. 9233141 - Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders (2016-01-12),

14. 9221891 - In vivo production of proteins (2015-12-29),

15. 9220792 - Modified polynucleotides encoding aquaporin-5 (2015-12-29),

Company Overview

Moderna Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, specializing in the development of messenger RNA (mRNA) therapeutics and vaccines. The company focuses on harnessing the potential of mRNA to create innovative treatments for a range of diseases, including infectious diseases, cancer, and rare genetic disorders. By leveraging its proprietary mRNA technology platform, Moderna aims to revolutionize the way medicines are developed and delivered, contributing to advancements in personalized medicine and public health.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

34 Patents

#85 in Cambridge, MA

#606 in Massachusetts

#10,022 in US

#19,651 in the World

Cambridge, MA, United States of America

Moderna Therapeutics, Inc.

Forward Citations = 3,728

21 inventors:

Antonin De Fougerolles (29 out of 91 patents)

Tirtha Chakraborty (20 out of 45 patents)

Jason P Schrum (13 out of 30 patents)

4. Stephane Bancel (9 out of 31 patents)

5. Sayda Mahgoub Elbashir (8 out of 57 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Moderna Therapeutics, Inc.. Retrieved from https://idiyas.com/company/moderna-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…